| Primary Name | Lupus Anticoagulant Profile |
| Synonym | Non-specific inhibitor |
| Synonym | -- |
| Contraction | LAC |
| Contraction | LA |
| Contraction | -- |
| UAB Procedure Number | 2500310, 2500725, 2500359, 2500305 |
| CPT Code | 85730, 85732, 85613, 85597 |
| Specimen | Collect three (3) blue-stopper tubes (3.2% sodium citrate), filled to specified volume. Do not underfill or overfill. |
| Specimen Management | Centrifuge blue-stopper tubes within one (1) hour of collection, separate plasma. Recentrifuge plasma so that it is platelet-poor and test or quick-freeze at -70°C. |
| Specimen Accepted | Daily including weekends |
| Test Performed | Two days a week |
| Available Stat? | No. |
| Description | LAC is an acquired non-specific inhibitor that is detected in 1-2% of individuals. Chronic lupus anticoagulant is associated with a 30% risk of venous thromboembolic disease or arterial thrombosis, including stroke and myocardial infarction. LAC is also associated with chronic spontaneous abortion. |
| Critical Value | None |
| Follow-up Test | *The lupus anticoagulant profile is a series of clotting assays based on the PTT-LA and the DRVVT with follow-up mixing studies and neutralization stages. *A positive lupus anticoagulant profile should be repeated on a new specimen after 12 weeks to determine if the inhibitor is transient or chronic. *The anticardiolipin antibody and the anti-beta2-glycoprotein I immunoassays are recommended for a complete workup of possible antiphospholipid syndrome. *The diagnosis of antiphospholipid antibidy syndrome requires a clinical history of thrombosis and a positive laboratory test for LAC or anticardiolipin antibodies that persist for 12 weeks. |
| Associated With | Venous thrombosis |
| Associated With | Arterial thrombosis |
| Associated With | Lupus anticoagulant |
| Associated With | Spontaneous abortions |
| Associated With | Coagulation factor inhibitors |
© Copyright by the University of Alabama at Birmingham